Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model.
about
Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer TherapyOn the origin of cancer metastasisCancer stem cell metabolism: a potential target for cancer therapyA metabolic perturbation by U0126 identifies a role for glutamine in resveratrol-induced cell death.Neurological sequelae induced by alphavirus infection of the CNS are attenuated by treatment with the glutamine antagonist 6-diazo-5-oxo-l-norleucineNon-Toxic Metabolic Management of Metastatic Cancer in VM Mice: Novel Combination of Ketogenic Diet, Ketone Supplementation, and Hyperbaric Oxygen Therapy.Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung CancerRole and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer.Cancer as a metabolic disease: implications for novel therapeutics.Altered glutamine metabolism and therapeutic opportunities for lung cancer.High glucose levels boost the aggressiveness of highly metastatic cholangiocarcinoma cells via O-GlcNAcylationGlutamine: pleiotropic roles in tumor growth and stress resistance.Metabolic alterations in cancer cells and therapeutic implications.The molecular profile of microglia under the influence of glioma.Non-invasive molecular imaging for preclinical cancer therapeutic development.Alteration of mitochondrial proteome due to activation of Notch1 signaling pathway.Drug-induced amino acid deprivation as strategy for cancer therapy.Comparison of different methods for erythroid differentiation in the K562 cell line.Therapeutic Targeting of Epithelial Plasticity Programs: Focus on the Epithelial-Mesenchymal Transition.Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors.Glutamine antagonist-mediated immune suppression decreases pathology but delays virus clearance in mice during nonfatal alphavirus encephalomyelitis.Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer.Press-pulse: a novel therapeutic strategy for the metabolic management of cancer.Bioanalysis of 6-diazo-5-oxo-l-norleucine in plasma and brain by ultra-performance liquid chromatography mass spectrometry.Membrane lipid profile alterations are associated with the metabolic adaptation of the Caco-2 cells to aglycemic nutritional condition.Depletion of glutamine enhances sodium butyrate-induced erythroid differentiation of K562 cells.Cancer stem cells (CSCs): metabolic strategies for their identification and eradication.Increased glutamine anabolism sensitizes non-small cell lung cancer to gefitinib treatmentHuman Dendritic Cell Subsets Undergo Distinct Metabolic Reprogramming for Immune Response
P2860
Q26783189-DFEF0D78-46AA-4C74-8C89-3B7983EAA720Q26865675-9E07E738-DB43-42C7-9378-650FBF926E1BQ28079045-4A5A9D0F-EEA4-4BF6-B70F-7057CF92891AQ30423585-CD8B4094-BB22-4398-BF73-DD3E97314D62Q35220415-6756C182-0399-455F-A6A0-B7CA2A70E2BBQ35660112-8F72EC96-D7E3-425B-AD03-B9A1B6A2ACF4Q36279031-A92A0D0D-F83D-40B1-AE09-CD13C289F81EQ36414207-FED90F28-3D44-4396-BA8A-187EFE2D1C1DQ37616057-AB5861AE-5D4E-43A8-9290-9012271D0B48Q37673339-18AAC153-FEA6-4939-82B9-92E170BD9A17Q37682200-7CFD4913-4CB8-4AB3-8539-BE7F0BF63DC7Q37837590-F2A2F3D3-F825-4F40-AD42-869F12070C1CQ37908233-78DAA281-C7C1-449A-84AF-27934C9C479EQ38008966-9481199A-BAF9-4696-A3BC-25242B2CE10FQ38089102-005B2722-95C9-4DD7-A7D3-80CB6F2C9DB8Q38268131-DB6E93B6-8328-43EC-94DC-AE6F9A9F5C4CQ38657061-4F2C485D-FC40-4356-8857-A17756B62E6AQ38778462-7AD42087-86B7-43EE-A615-8B7D31CF71BEQ38953751-03593092-8E0C-40C5-BADA-6A2EFE848D08Q39026261-3F6FC2F1-8328-41FA-9B43-4B706539A62AQ40190862-E345F87B-5310-4B1F-9652-C7D42ACF4924Q41366826-C5798B93-12C3-4A2F-B7C0-B0BCD5E66A74Q41989445-B5FCCB81-B80D-42AB-B1F7-C99559AA279DQ42026016-C5E6F7F5-6615-4161-B350-8FA01C6F313DQ46225686-6F5341DF-DA49-46FD-B72F-578649B211DFQ54488059-4888B1A6-35FB-4C53-9983-D1108A3FC9C9Q55254924-0BC6B2E7-8BD0-4FD4-97A2-89414AB9B083Q58793684-02B90B1F-59F4-48A8-BE89-BB320E25C180Q59129979-C0C337D3-05D9-4C81-AB30-D906512C1379
P2860
Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model.
@ast
Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model.
@en
Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model.
@nl
type
label
Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model.
@ast
Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model.
@en
Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model.
@nl
prefLabel
Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model.
@ast
Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model.
@en
Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model.
@nl
P2860
P356
P1476
Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model.
@en
P2093
Laura M Shelton
Leanne C Huysentruyt
P2860
P304
P356
10.1002/IJC.25431
P577
2010-11-01T00:00:00Z